Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
4 "Neuroendocrine tumors"
Filter
Filter
Article type
Keywords
Publication year
Authors
Funded articles
Review Article
Hypothalamus and pituitary gland
Update on Current Evidence for the Diagnosis and Management of Nonfunctioning Pituitary Neuroendocrine Tumors
Elizabeth Whyte, Masahiro Nezu, Constance Chik, Toru Tateno
Endocrinol Metab. 2023;38(6):631-654.   Published online November 15, 2023
DOI: https://doi.org/10.3803/EnM.2023.1838
  • 2,368 View
  • 150 Download
  • 1 Crossref
AbstractAbstract PDFPubReader   ePub   
Pituitary neuroendocrine tumors (PitNETs) are the third most frequently diagnosed intracranial tumors, with nonfunctioning PitNETs (nfPitNETs) accounting for 30% of all pituitary tumors and representing the most common type of macroPitNETs. NfPitNETs are usually benign tumors with no evidence of hormone oversecretion except for hyperprolactinemia secondary to pituitary stalk compression. Due to this, they do not typically present with clinical syndromes like acromegaly, Cushing’s disease or hyperthyroidism and instead are identified incidentally on imaging or from symptoms of mass effects (headache, vision changes, apoplexy). With the lack of effective medical interventions, first-line treatment is transsphenoidal surgical resection, however, nfPitNETs often have supra- or parasellar extension, and total resection of the tumor is often not possible, resulting in residual tumor regrowth or reoccurrence. While functional PitNETs can be easily followed for recurrence using hormonal biomarkers, there is no similar parameter to predict recurrence in nfPitNETs, hence delaying early recognition and timely management. Therefore, there is a need to identify prognostic biomarkers that can be used for patient surveillance and as therapeutic targets. This review focuses on summarizing the current evidence on nfPitNETs, with a special focus on potential new biomarkers and therapeutics.

Citations

Citations to this article as recorded by  
  • Phenotype Transformation of PitNETs
    Zhenwei Li, Yinzi Wu, Guannan He, Renzhi Wang, Xinjie Bao
    Cancers.2024; 16(9): 1731.     CrossRef
Close layer
Case Reports
Thyroid
A Calcitonin-Negative Neuroendocrine Tumor Derived from Follicular Lesions of the Thyroid
Ga Young Kim, Chul Yun Park, Chang Ho Cho, June Sik Park, Eui Dal Jung, Eon Ju Jeon
Endocrinol Metab. 2015;30(2):221-225.   Published online December 9, 2014
DOI: https://doi.org/10.3803/EnM.2015.30.2.221
  • 3,392 View
  • 30 Download
  • 7 Web of Science
  • 8 Crossref
AbstractAbstract PDFPubReader   

Neuroendocrine lesions of the thyroid are rare. The most common types are medullary thyroid carcinomas (MTCs) and C-cell hyperplasia. MTCs originate from thyroid parafollicular cells that secrete calcitonin which serves as a serum marker of MTCs. Here, the rare case of a calcitonin-negative neuroendocrine tumor (NET) derived from follicular lesions of the thyroid is described. A 34-year-old man presented at our hospital for the surgical management of an incidental thyroid nodule that was observed on an ultrasound sonography (USG) of the neck. Initially, USG-guided aspiration cytology was performed, and a MTC was suspected. The expressions of thyroglobulin and thyroid transcription factor-1, which are thyroid follicular cell markers, and synaptophysin and chromogranin A, which are neuroendocrine markers, was confirmed following surgical pathology. However, the staining of calcitonin, a marker of MTCs, was not observed. A nonmedullary NET of the thyroid is uncommon, and the distinction between calcitonin-negative NETs and MTCs of the thyroid may be important due to differences in their clinical courses and management.

Citations

Citations to this article as recorded by  
  • Calcitonin-Negative Neuroendocrine Carcinoma of the Thyroid Gland: Case Report and Literature Review
    Ricardo Fernández-Ferreira, Ildefonso Roberto De la Peña-López, Karla Walkiria Zamudio-Coronado, Luis Antonio Delgado-Soler, María Eugenia Torres-Pérez, Christianne Bourlón-de los Ríos, Rubén Cortés-González
    Case Reports in Oncology.2021; 14(1): 112.     CrossRef
  • Calcitonin-negative neuroendocrine tumor of the thyroid with metastasis to liver-rare presentation of an unusual tumor: A case report and review of literature
    Huai-Jie Cai, Han Wang, Nan Cao, Bin Huang, Fan-Lei Kong, Li-Ren Lu, Ya-Yuan Huang, Wei Wang
    World Journal of Clinical Cases.2020; 8(1): 179.     CrossRef
  • Medullary thyroid carcinoma with double negative calcitonin and CEA: a case report and update of literature review
    Claudio Gambardella, Chiara Offi, Guglielmo Clarizia, Roberto Maria Romano, Immacolata Cozzolino, Marco Montella, Rosa Maria Di Crescenzo, Massimo Mascolo, Angelo Cangiano, Sergio Di Martino, Giancarlo Candela, Giovanni Docimo
    BMC Endocrine Disorders.2019;[Epub]     CrossRef
  • Calcitonin negative Medullary Thyroid Carcinoma: a challenging diagnosis or a medical dilemma?
    Claudio Gambardella, Chiara Offi, Renato Patrone, Guglielmo Clarizia, Claudio Mauriello, Ernesto Tartaglia, Francesco Di Capua, Sergio Di Martino, Roberto Maria Romano, Lorenzo Fiore, Alessandra Conzo, Giovanni Conzo, Giovanni Docimo
    BMC Endocrine Disorders.2019;[Epub]     CrossRef
  • Calcitonin-Negative Neuroendocrine Tumor of the Thyroid
    Megan Parmer, Stacey Milan, Alireza Torabi
    International Journal of Surgical Pathology.2017; 25(2): 191.     CrossRef
  • Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin
    Qiufeng Zhou, Shuanglei Yue, Ye Cheng, Ju Jin, Haimiao Xu
    Experimental and Toxicologic Pathology.2017; 69(8): 575.     CrossRef
  • Primary Calcitonin-negative Neuroendocrine Tumor
    Sabri Özden, Aysel Colak, Baris Saylam, Ömer Cengiz
    World Journal of Endocrine Surgery.2017; 9(3): 104.     CrossRef
  • LONG-TERM RESULTS OF SURGICAL TREATMENT OF PATIENTS WITH FOLLICULAR TUMORS OF THE THYROID
    I. N. Zubarovskiy, M. V. Mikhailova, S. K. Osipenko
    Grekov's Bulletin of Surgery.2015; 174(5): 32.     CrossRef
Close layer
A Case of Ectopic ACTH Syndrome Associated with Metastatic Prostate Cancer.
Eun Ky Kim, Soo Heon Kwak, Hwa Young Ahn, Ah Reum Khang, Hyo Jin Park, So Yeon Park, Sang Eun Lee, Hak Chul Jang, Seong Yeon Kim, Young Joo Park
Endocrinol Metab. 2012;27(3):237-243.   Published online September 19, 2012
DOI: https://doi.org/10.3803/EnM.2012.27.3.237
  • 1,809 View
  • 26 Download
AbstractAbstract PDF
Ectopic adrenocorticotropic hormone (ACTH) syndrome is mostly associated with neuroendocrine tumors and small cell carcinoma of the lung. This syndrome of prostate cancer is rare and has been reported in only a few cases. We report a patient with ectopic ACTH production associated with metastatic prostate cancer. A 70-year-old patient with metastatic prostate cancer was admitted to our hospital with septic shock. He had a history of hormonal therapy and transurethral prostatectomy. Adrenocortical function was checked due to consistent fever and poor general condition, which revealed markedly increased levels of basal plasma ACTH and serum cortisol. The patient did not present typical signs of the Cushing's syndrome, however, hypokalemia and a history of hypertension were found. He died in days as a result of multi-organ failure. On pathology, the prostatectomy specimen showed a tumor composed of mixed populations of adenocarcinoma and small cell carcinoma. The tumor cells in the small cell component were positive for chromogranin and ACTH. Although neuroendocrine differentiation in prostate cancer is rare, etopic ACTH production should be considered in patients with prostate cancer as well as in clinical features of ACTH hypersecretion.
Close layer
A Case of von Hippel-Lindau Disease Presenting with Pancreatic Neuroendocrine Tumor.
Jung Hun Ohn, Junghee Kim, Hyun Jung Lee, Won Woo Seo, Yul Hwang-Bo, Eun Shil Hong, Jin Joo Park, Seong Yeon Kim
Endocrinol Metab. 2011;26(1):89-91.   Published online March 1, 2011
DOI: https://doi.org/10.3803/EnM.2011.26.1.89
  • 1,994 View
  • 20 Download
  • 1 Crossref
AbstractAbstract PDF
Von Hippel-Lindau (VHL) disease is an autosomal dominant disorder that results from a germline mutation of the VHL gene. The affected individuals might develop several benign or malignant tumors such as central nervous system or retinal haemangioblastomas, endolymphatic sac tumors, renal cell carcinomas, pheochromocytomas or pancreatic cysts and neuroendocrine tumors. We report here on a case of a 21 year old female with von Hippel-Lindau disease and she presented with only pancreatic neuroendocrine tumor and no evidence of haemangioblastomas or other visceral complications. Further, direct sequencing of the VHL gene reveals a novel germline frameshift mutation of codon 198 from the deletion of nucleotide 592 (cytosine), leading to truncation of the VHL protein.

Citations

Citations to this article as recorded by  
  • Germline mutation of Glu70Lys is highly frequent in Korean patients with von Hippel–Lindau (VHL) disease
    Sena Hwang, Cheol Ryong Ku, Ji In Lee, Kyu Yeon Hur, Myung-Shik Lee, Chul-Ho Lee, Kyo Yeon Koo, Jin-Sung Lee, Yumie Rhee
    Journal of Human Genetics.2014; 59(9): 488.     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism